SplitKits for trypsin-free cell harvesting
Vegetable-based system offers gentler, more efficient and contamination-free dissociation
Developed using a vegetable-based component rather than trypsin, SplitKits avoid any risk of contamination with either animal or human viruses or bacteria, and are suitable for a variety of cell culture systems.
Independent studies conducted in both research and biopharmaceutical laboratories have shown that SplitKits also encourage faster cell dissociation than trypsin. Greater control of the dissociation process produces homogeneous cell suspensions with minimal batch-to-batch variation, the company says.
According to Sera, the gentle action of the SplitKits vegetable-based enzyme gives higher cell yields and better cell growth recovery following detachment. In addition, surface epitopes and cell membranes remain unaltered and fully functional, making the kits suitable for use in flow cytometry.
‘Drawing on 30 years of experience in cell culture, we have developed SplitKits to offer a significantly improved alternative to trypsin,’ said Jenny Murray, Sera Lab’s managing director. ‘For use in both laboratory cell culture and biopharmaceutical manufacturing, the increasing regulation of the use of animal-based components in the biopharmaceutical manufacturing environment means that SplitKits also offer the industry a potentially safer, more compliant system for cell culture.’
Each SplitKit comprises a vegetable-based enzymatic reagent (SplitCells), AntiSplitCells and a SplitCells buffer. There are three formats in the SplitKits range, each being optimised for use with specific cell types: SplitKit Strong, for strongly adherent and bioreactor-cultured cells; SplitKit Moderate for moderately adherent cells; and SplitKit Mild for mildly adherent cells.
You may also like
Regulatory
Analytical vigilance saves lives
Read moreThe EDQM has updated Ph. Eur. monographs to detect ethylene glycol and diethylene glycol. Butterworth Laboratories supports compliance through validated chromatographic testing, impurity screening, and documentation—helping pharmaceutical companies ensure product safety and protect patient lives
Trending Articles
You may also like
Regulatory
Analytical vigilance saves lives
The EDQM has updated Ph. Eur. monographs to detect ethylene glycol and diethylene glycol. Butterworth Laboratories supports compliance through validated chromatographic testing, impurity screening, and documentation—helping pharmaceutical companies ensure product safety and protect patient lives
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Lonza receives Swissmedic approval for new high-potency biologics filling line in Stein
Lonza’s state-of-the-art aseptic filling line in Stein, Switzerland, has been granted GMP approval by Swissmedic, expanding the CDMO’s capacity for biologics and antibody-drug conjugates while strengthening its integrated, end-to-end manufacturing offering
Analysis
Global biopharma faces talent shortages and regulatory uncertainty, Cytiva’s 2025 Global Biopharma Index finds
Cytiva’s latest Global Biopharma Index, surveying 1250 executives across 22 countries, reveals that while supply chain resilience is improving, talent shortages and policy instability are threatening growth across the biopharma sector
Manufacturing
Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia
Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals
People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS